Knowledge Transfer Series


An online environment designed to promote, educate and share information about the burden of seasonal influenza and its presence in the United States.

Home / Publications



  1. Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015–16 Influenza Season

    Lisa A. Grohskopf, MD; Leslie Z. Sokolow, MSc, MPH; Sonja J. Olsen, PhD; et al. -- 2015.

    Centers for Disease Control and Prevention - Morbidity and Mortality Weekly Report - August 7, 2015. Read More

  2. Understanding the Challenges and Opportunities in Protecting Older Adults from Influenza, A Brief from the NFID

    Arnold Monto, MD; Kristin Nichol, MD, MPH; H. Keipp Talbot, MD, MPH; William Schaffner, MD -- 2011.

    People of all ages can become infected with influenza virus, but the infection is particularly serious in older adults. Read More

  3. Immunosenescence: Influenza vaccination and the elderly.

    Haq K, McElhaney JE -- 2014.

    Aging is associated with a decline in the normal function of the immune system, both cellular and humoral, which often leads to a state of 'immunosenescence'. Read More

  4. Influenza Vaccine Responses in Older Adults

    McElhaney JE -- 2011.

    The most profound consequences of immune senescence with respect to public health are the increased susceptibility to influenza and loss of efficacy of the current split-virus influenza vaccines in older adults, which are otherwise very effective in younger populations. Read More

  5. Traditional and New Influenza Vaccines

    Sook-San Wong and Richard J. Webby -- 2013.

    The challenges in successful vaccination against influenza using conventional approaches lie in their variable efficacy in different age populations, the antigenic variability of the circulating virus, and the production and manufacturing limitations to ensure safe, timely, and adequate supply of vaccine. Read More

  6. The Compelling Need for Game-Changing Influenza Vaccines, An Analysis of the Influenza Vaccine Enterprise and Recommendations for the Future

    Osterholm MT, Kelley NS, Manske JM, Ballering KS, Leighton TR, Moore KA -- 2012.

    Dating back to Hippocrates, influenza has been and continues to be one of the “lion kings” of infectious diseases. Read More

  7. Influenza Vaccines for the Future

    Lambert LC, Fauci AS -- 2010.

    Each year, seasonal epidemics of influenza cause serious illness and death throughout the world. In the United States, the annual burden of disease is estimated to be 25 million to 50 million cases of influenza, resulting in an average of 225,000 hospitalizations. Read More

  8. Vaccination in the elderly: an immunological perspective.

    Chen WH, Kozlovsky BF, Effros RB, et al. -- 2009.

    Successful vaccination of the elderly against important infectious pathogens that cause high morbidity and mortality represents a growing public health priority. Read More

  9. Efficacy of high-dose versus standard-dose influenza vaccine in older adults

    DiazGranados CA, Dunning AJ, Kimmel M, et al. -- 2012.

    As compared with a standard-dose vaccine, a high-dose, trivalent, inactivated influenza vaccine (IIV3-HD) improves antibody responses to influenza among adults 65 years of age or older. This study evaluated whether IIV3-HD also improves protection against laboratory-confirmed influenza illness. Read More

  10. FDA Advisory Panel Recommends Licensure of NVS Influenza Candidate Vaccine for Protection Against Seasonal Influenza in the Elderly

    CAMBRIDGE, Mass., Sept. 15, 2015 /PRNewswire/

    NVS Influenza Vaccines, now owned and operated by the CSL Limited, announced today that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the US Food and Drug Administration (FDA) voted to recommend licensure of a candidate vaccine to help protect against seasonal influenza in those aged 65 years and older via accelerated approval. Read More

  11. Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty.

    DiazGranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, Greenberg DP -- 2015.

    A randomized trial demonstrated that a high-dose inactivated influenza vaccine (IIV-HD) was 24.2% more efficacious than a standard-dose vaccine (IIV-SD) against laboratory-confirmed influenza illness in adults ≥65 years. Read More

  12. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis

    Hector S Izurieta, MD; Nicole Thadani, BS; David K Shay, MD; et al. -- 2015.

    A high-dose trivalent inactivated influenza vaccine was licensed in 2009 by the US Food and Drug Administration (FDA) on the basis of serological criteria. We sought to establish whether high-dose inactivated influenza vaccine was more effective for prevention of influenza-related visits and hospital admissions in US Medicare beneficiaries than was standard-dose inactivated influenza vaccine. Read More

  13. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons.

    Keitel WA, Atmar RL, Cate TR, et al. -- 2006.

    Immune responses after influenza immunization are reduced in elderly individuals, the group at greatest risk for complications and death after influenza. Improved vaccines are needed to address this problem. Read More

  14. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly.

    Van Buynder PG1, Konrad S, Van Buynder JL, et al. -- 2013.

    Influenza is associated with a high mortality and morbidity in older adults. Vaccination remains the most effective method of preventing influenza and its consequences, however, vaccine effectiveness decreases with increasing age and increasing immunosenescence. Read More

  15. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy.

    Mannino S, Villa M, Apolone G, et al. -- 2012.

    Although vaccination against influenza is recommended for elderly and high-risk patients in many countries, efficacy in the elderly has been suboptimal. Read More

  16. Questions and Answers, Vaccine effectiveness estimates for seasonal influenza vaccines

    World Health Organization (WHO) -- 2015.

    What is the vaccine effectiveness of seasonal influenza vaccines? How is vaccine effectiveness measured? What factors influence the vaccine effectiveness estimate? Read More

  17. Early Estimates of Seasonal Influenza Vaccine Effectiveness — United States, January 2015

    Brendan Flannery, PhD, Jessie Clippard, MPH, Richard K. Zimmerman, MD, et al. -- 2015.

    In the United States, annual vaccination against seasonal influenza is recommended for all persons aged ≥6 months. Each season since 2004–05, CDC has estimated the effectiveness of seasonal influenza vaccine in preventing medically attended acute respiratory illness (ARI) associated with laboratory-confirmed influenza. Read More

  18. Vaccines, 6th Edition

    Plotkin S, Orenstein WA, Offit P. -- 2013.

    Find all the details you need to know about vaccinations -  a detailed perspective of each disease. Read More

Featured Video

ICID Grand Rounds

Watch the experts discuss flu vaccines for little kids - What's new, what's true?


Featured Physician Resource

CDC Key Facts about Influenza (Flu) & Flu Vaccine

The flu basics - everything you need to know about influenza and the flu vaccine.

This resource centre is supported in part by an unrestricted educational grant from

Powered By